Trials / Completed
CompletedNCT00900614
Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
An Open-label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Aprea Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APR-246 | Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level. |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2009-05-13
- Last updated
- 2019-07-31
Locations
6 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00900614. Inclusion in this directory is not an endorsement.